Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


February 11, 2016

Date of Report

(Date of earliest event reported)



(Exact name of registrant as specified in its charter)


Colorado   000-55013   20-4387296
(State or other jurisdiction
of Incorporation)
File Number)
  (IRS Employer
Identification No.)


10 Boulder Crescent, Suite 102, Colorado Spring, CO 80903

(Address of principal executive offices, including zip code)


(719) 219-5797

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ]   Written communications pursuant to Rule 425 under the Securities Act


[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act


[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act


[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act






Item 1.01 Entry into a Material Definitive Agreement.


On the February 11, 2016, STL Marketing Group, Inc. (the “Company”) entered into a licensing agreement with Camposagrado, Inc. (the “Agreement”) whereby the Company will exclusively develop, sell and commercialize Camposagrado, Inc.’s Application (U.S. Application No. 14/877,595) under US Trademark F3TCH, USPTO Date Applied: October 7, 2015.


Under the terms of the Agreement, the Company will pay $50,000.00 within the first three (3) years for the exclusivity and worldwide rights and three percent (3%) of any sales to Camposagrado. Inc. for any sales under the licensed technology. The Agreement allows the use of the patent pending technology as well as any trademarks.


The foregoing information is a summary of the Agreement involved in the transaction described above, is not complete, and is qualified in its entirety by reference to the full text of the Agreement, which is attached as an exhibit to this Current Report on Form 8-K. Readers should review the Agreement for a complete understanding of the terms and conditions of the transaction described above.


Item 8.01 Other Events.


The Securities and Exchange Commission (the “SEC”) has provided guidance to issuers regarding the use of social media to disclose material non-public information. In this regard, investors and others should note that in addition to our SEC filings, press releases, public conference calls and webcasts, we may announce material financial information on our website, www.v3rsant.com . We use these channels as well as social media to communicate with the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC’s guidance, we encourage investors, the media, and others interested in our company to also review the information we post on our social media sites including Facebook ( https://www.facebook.com/v3rsant/ ), LinkedIn account ( https://www.linkedin.com/company/versant-corporation?trk=nav_account_sub_nav_company_admin ), and Twitter ( https://twitter.com/F3tchApp ). These social media sites and their posts are also displayed on our main corporate page at http://www.v3rsant.com/versant-news.html.


On May 25, 2016, the Company created a new 51% owned subsidiary to handle the sale and commercialization of the Hound Software product that has been developed by Kinetos, S.A., a Costa Rican privately held corporation (“Kinetos”). Kinetos owns the remaining 49% of the subsidiary. This subsidiary named, Kinver Technologies, Inc. (“Kinver”), is a Florida corporation, in good standing.


Kinetos has already deployed the various software solutions with clients in Costa Rica and has more than twenty-five years in business. The Company has secured a web site for Kinver Technologies ( www.kinvertech.com ) that will be forwarded to the brand’s main site ( www.houndsoftware.net ) and will operate as a D/B/A in Colorado as Hound Software. The Company will consolidate Kinver’s financials as required.


The Hound Software platform is comprised of various modules that can be sold separately or as a suite- e.g. Data Wrangling and Automated Workflow. While software has ongoing and perpetual research and development, the product is viable, deployed and installed at clients’ sites and can be sold and deployed “as is” in the United States market immediately. Kinver will use that existing product to deploy and sell in the US market and plans to sell the software under the Software as a Service or SaaS model. For more information on Hound Software, please visit www.houndsoftware.net .


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits .    
  Exhibit Number   Description
  10.1   License Agreement with Camposagrado, Inc.






Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: June 8, 2016  
  /s/ Jose P. Quiros
  Jose P. Quiros
  Principal Executive Officer




Camposagrado, Inc. & STL Marketing Group, Inc.

Patent & Trademark Licensing Agreement


THIS AGREEMENT, effective this 11 th day, of February 2016, is entered into by Camposagrado, Inc. (hereinafter “LICENSOR”) and STL Marketing Group, Inc. (hereinafter “LICENSEE”).




WHEREAS, LICENSOR has designed and developed an application for creating a virtual hotel guest room telephone to be used with a guest’s own, or any smart phone or device, in a hotel environment (hereinafter “INVENTION”).


WHEREAS, LICENSOR is the owner of all rights, title and interest in the INVENTION and has filed for a patent with the United States Patent & Trademark Office under Application No. 14/877,595, as well as filed for trademark rights on the brand name F3TCH.


WHEREAS, LICENSOR desires to transfer to LICENSEE and LICENSEE desires to acquire from LICENSOR an exclusive license to develop and market the INVENTION covered by the patent rights in the USA and all other countries, territories and jurisdictions on the terms and conditions set forth in this Agreement.


NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, parties agree as follow:




1.1. GROSS SALES. “Gross Sales” shall mean the aggregate compensation the LICENSEE, or its subsidiaries, or mutually agreed joint ventures, receives for goods sold under the Patent Rights without a reduction for taxes, transportation, returns, depreciation or other expenses.


1.2. CLOSING. “Closing” shall occur when both LICENSOR and LICENSEE have applied their respective signatures to this Agreement.


1.3. PATENT & TRADEMARK RIGHTS. “Patent & TRADEMARK Rights” means the following listed patents and/or patent applications, patents to be issued pursuant thereto, and all divisions, continuations, reissues, substitutes, and extensions thereof as well as any trademarks listed:


Applications/ Trademarks


  (a) U.S. Application No. 14/877,595
  (b) US Trademark F3TCH, USPTO Date Applied: October 7, 2015.




In consideration for the up-front monies and royalty to be paid under Sections 3 and 4, LICENSOR grants to LICENSEE:


(a) an exclusive, nontransferable license to develop and market the INVENTION globally;
(b) all rights under the Patent & Trademark Rights; and
(c) all technology, trade secrets and know-how related to the design and manufacture of the INVENTION, including all design plans, blueprints and any documentation or software related thereto.






LICENSEE shall pay to LICENSOR, as soon as possible, within three years of the date of Closing, seventy-five thousand (US$75,000.00) in United States funds. The up-front monies are not to be considered part of the royalties due under Section 4 of this Agreement.




Upon Closing, LICENSEE shall pay LICENSOR a royalty payment based upon the Gross Sales of the LICENSEE. Said royalty payment shall be calculated based upon 3% of the Gross Sales of the LICENSEE with regard to the Invention.




5.1. QUARTERLY PAYMENTS. LICENSEE shall pay LICENSOR a royalty for each calendar quarter of each year during which this Agreement is in effect, net 30.


5.2 MINIMUM PAYMENT. There is no minimum quarterly royalty payment if there are no sales with regard to the INVENTION.




6.1. FINANCIAL STATEMENT. LICENSEE shall provide a quarterly financial statement to LICENSOR showing the Gross Sales during each quarter when each quarterly royalty payment is made.


6.2. RECORDS. LICENSEE shall keep records of the Gross Sales and numbers supporting these figures pursuant to this Agreement in sufficient detail to enable the royalty payment to LICENSOR to be determined.


6.3. ANNUAL INSPECTION. LICENSEE shall allow LICENSOR’s representative, one annual inspection, during regular business hours or at such other times as may be mutually agreeable, to inspect LICENSEE’s books and records to the extent reasonably necessary to determine LICENSEE’s compliance with the terms of this Agreement.


6.4. PENALTY. If the LICENSOR determines through an annual inspection that the LICENSOR was undercompensated as required by this Agreement, then the LICENSEE shall pay to the LICENSOR a Penalty Fee. The Penalty Fee shall comprise three times the difference between the actual compensation and the required compensation. The LICENSEE shall still be obligated to pay full compensation as required under the Agreement.




The LICENSOR agrees with the LICENSEE to execute such documents and give such assistance as the LICENSEE may reasonably require:


(a) to defeat any challenge to the validity of, and resolve any questions concerning the Patent Rights;
(b) to apply for and obtain patents or similar protection for the INVENTION in other parts of the world at the LICENSEE’s expense;
(c) to do all that is necessary to vest such protection in the LICENSEE;
(d) to inform the LICENSEE of all technical information concerning the INVENTION; and
(e) to supply the LICENSEE with any documents or drawings relevant to the INVENTION.






8.1. LICENSOR represents and warrants to LICENSEE as follows:


(a) LICENSOR is the sole and exclusive owner of the INVENTION and the Patent Rights. No other parties have any right or interest in or to the INVENTION nor to the Patent Rights;
(b) All rights to the INVENTION and the Patent Rights are free and clear of all liens, claims, security interests and other encumbrances of any kind or nature;
(c) The LICENSOR has not granted any licenses to use the INVENTION to any other parties;
(d) LICENSOR has the right and power to enter into this Agreement, and has made no prior transfer, sale or assignment of any part of the INVENTION, patent rights pertaining to the INVENTION or the Patent Rights;
(e) As of the date hereof and as of the Closing date, LICENSOR is not aware of any parties infringing on the patent rights transferred hereunder;
(f) LICENSOR is not aware that the INVENTION infringes upon any patent, but LICENSOR does not otherwise warrant or guarantee the validity of the Patent Rights or that the INVENTION does not infringe any valid and subsisting patent or other rights not held by the LICENSOR; and
(g) The INVENTION was not procured by the use of confidential information, trade secrets, or in other respects in violation of law, and there is no action, order or proceeding, to the LICENSOR’s knowledge, alleging any of the foregoing.


8.2. Each of the warranties and representations set forth above shall be true on and as of the date of Closing, as though such warranty and representation was made as of such time. All warranties and representations shall survive closing.




9.1. INDEMNIFICATION. The LICENSEE agrees to indemnify the LICENSOR and his heirs successors, assigns and legal representatives for liability incurred to persons who are injured as a consequence of the use of any INVENTION developed or implemented by the LICENSEE or as a consequence of any defects in the INVENTION.


9.2. QUARTERLY ROYALTY. The LICENSEE agrees to pay the above stated quarterly royalty without demand.


9.3. REASONABLE EFFORTS. The LICENSEE agrees to utilize all reasonable efforts to commercialize and market the INVENTION.


9.4. FINANCIAL STATEMENT. The LICENSEE agrees to provide the financial statement at the end of each quarter without demand.


9.5. PROFESSIONALISM. The LICENSEE agrees to the extent reasonably possible, have all manufacturing, shipping, and sales performed in a professional and equitable manner.


9.6. LIABILITY INSURANCE. The LICENSEE agrees to maintain liability insurance to cover the INVENTION in an amount greater than or equal to $1,000,000 once the INVENTION begins to be implemented.


9.7. TRADE SECRETS. The LICENSEE agrees to take all reasonable steps to maintain the confidentiality of all trade secrets provided by the LICENSOR to the LICENSEE during and after this Agreement.






LICENSEE’s obligation to pay the up-front monies and the royalty shall be subject to the satisfaction as stipulated in Section 3 above, any one or more which may be waived by LICENSEE:


(a) The warranties and representations made by the LICENSOR in this Agreement shall be true and correct in all material respects on the Closing date as if such warranties and representations had been given as of the Closing date.


(b) LICENSOR shall have delivered to LICENSEE such instruments of transfer as may be reasonably requested by LICENSEE to consummate the transactions contemplated hereby.




LICENSEE agrees to affix patent pending and patent notices to all INVENTIONs prior to their sale in accordance with 35 U.S.C. §282. Each device shall have either the words “PATENT PENDING” or “Patent No.” followed by the patent number conspicuously marked on each of the goods sold under the Patent Rights subject to the reasonable approval of the LICENSOR.




12.1 This Agreement shall remain in full force and effect unless and until termination or cancellation as hereinafter provided.


12.2. If LICENSEE shall at any time default in rendering any of the statements required hereunder, and payment of any monies due hereunder, or in fulfilling any of the other material obligations hereof, and such default is not cured within fifteen days after written notice is given by the LICENSOR to LICENSEE, LICENSOR shall have the right to terminate this Agreement by giving written notice of termination to LICENSEE. LICENSEE shall have the right to cure any such default up to, but not after the written notice of termination.


12.3 It is understood that LICENSEE is a publicly traded company and that there are existing conditions of default in some of its debt, as well as an existing 3(a)10. LICENSOR shall have the right to terminate this Agreement by giving written notice of termination to LICENSEE in the event of any of the following:


(a) liquidation of LICENSEE;
(b) future insolvency or bankruptcy of LICENSEE, whether voluntary or involuntary arising from new or preexisting obligations; or
(c) appointment of a Trustee or Receiver for LICENSEE.


12.4. LICENSOR shall have the right to terminate this Agreement, by giving three months written notice, if after the second year of this agreement the previous years total royalty payment is lower than one-hundred thousand dollars (US$100,000).


12.5. LICENSEE shall have the right to terminate this Agreement, by giving three months notice, if all patent applications, continuation, continuation-in-part or divisional applications, related to the INVENTION become abandoned without issuing into a patent.


12.6. LICENSEE shall have the right to terminate this Agreement, by giving three months notice, if a court of law determines all of the issued or pending patents to be invalid.




13.1. MAINTENANCE FEES. LICENSEE shall be responsible for paying all maintenance fees for the Patent Rights until they expire.


13.2. DEFENDING AN INFRINGEMENT LAWSUIT. LICENSEE shall be responsible for all expenses, including but not limited to legal fees, associated with defending an infringement action involving the INVENTION. LICENSEE also agrees to vigorously defend at its own expense any invalidity actions brought against the Patent Rights.




13.3. BRINGING AN INFRINGEMENT LAWSUIT. LICENSEE shall also be responsible for all expenses, including but not limited to legal fees, associated with bringing an infringement action involving the Patent Rights. LICENSEE agrees to initiate and vigorously prosecute proceedings to the termination of any infringements on the Patent Rights.


13.4. NOTIFICATION. LICENSEE and LICENSOR both agree to notify each other of any legal action involving the Patent Rights or the INVENTION.




Any controversy or claim arising out of or relating to this contract, or the breach thereof, between the LICENSOR and the LICENSEE shall be settled by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association in a convenient location in Colorado. The judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.




This Agreement shall be governed in accordance with the substantive laws of the State of Colorado of the United States of America.




16.1. The parties agree that if any part, term, or provision of this Agreement shall be found illegal or in conflict with any valid controlling law, the validity of the remaining provisions shall not be affected thereby.


16.2. In the event the legality of any provision of this Agreement is brought into question because of a decision by a court of competent jurisdiction, LICENSOR, by written notice to LICENSEE, may revise the provision in question or delete it entirely so as to comply with the decision of said court.




For the purposes of all written communications and notices between the parties, their addresses shall be:



Camposagrado, Inc.

Attn: Jose Quiros

5 East Bijou Street, #374

Colorado Springs, CO 80903

Email: jquiros@camposagraodinc.com


STL Marketing Group, Inc.

Attn: Ms. Jaime Kniep

10 Boulder Crescent, Suite 102

Colorado Springs, CO 80903

Email: Jaime@v3rsant.com




The parties agree this Agreement imposes specific obligations on LICENSEE. LICENSEE shall not assign any rights under this Agreement without the written consent of LICENSOR. LICENSOR may assign all rights hereunder.






This Agreement sets forth all of the covenants, promises, agreements, conditions and understandings between the parties and there are no covenants, promises, agreements or conditions, either oral or written, between them other than herein set forth. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon either party unless reduced in writing and signed by them.


IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized officers on the respective dates hereinafter set forth.


LICENSOR: /s/ Jose P. Quiros

Jose P. Quiros


LICENSEE /s/ Jaime Kniep

Jaime Kniep

Chief Financial Officer




Exhibit A

Summary of US Patent & Trademark Office Application for Patent




Exhibit B

Trademark Application with USPTO